Josep Carreras Leukaemia Research Institute and China’s IHCAMS Form Strategic Global Alliance to Accelerate Blood Cancer Therapeutics

The Josep Carreras Leukaemia Research Institute and China’s IHCAMS sign a strategic MoU to develop next-gen immunotherapies and curative blood cancer treatments.

By: AXL Media

Published: Mar 27, 2026, 9:14 AM EDT

Source: Information for this report was sourced from Josep Carreras Leukaemia Research Institute

The Transaction and Strategic Research Development

The formalization of a Memorandum of Understanding between the Josep Carreras Leukaemia Research Institute and the Institute of Hematology & Blood Diseases Hospital marks a significant consolidation of resources between European and Asian medical powerhouses. This agreement, signed during a high level institutional ceremony in Barcelona, establishes a structured framework for scientific cooperation aimed specifically at curing blood cancers. By aligning the IJC’s research capabilities with IHCAMS, which is part of the Chinese Academy of Medical Sciences, the institutions seek to create a unified front against leukemia and lymphoma. Dr Ari Melnick, Director of the IJC, noted that this collaboration is a practical necessity, as international environments are essential for moving laboratory discoveries into clinical settings more rapidly.

Regulatory and Competitive Landscape

In the increasingly competitive field of global oncology, the ability to validate biomarkers across diverse genetic populations provides a distinct regulatory and scientific advantage. This partnership bypasses traditional geographic silos by creating shared disease profiling platforms that can satisfy the rigorous data requirements of multiple international health authorities. The involvement of Carme Pérez from the Catalan Department of Health and Antoni Garcia of the Josep Carreras International Foundation underscores the institutional backing this alliance enjoys within the broader European healthcare regulatory framework. By integrating infrastructure, the two entities are positioned to lead in the standardization of precision medicine protocols for hematologic malignancies.

Strategic Rationale and Market Impact

The strategic logic behind the alliance centers on the complementary nature of the two institutions’ technological and clinical assets. IHCAMS brings a massive patient-centered study infrastructure and rapid technological growth, while the IJC offers fifteen years of specialized excellence in molecular profiling and pediatric leukemia research. According to Prof Tao Cheng, President of IHCAMS, the integration of these infrastructures is essential for the next phase of blood science. The market for blood cancer treatments is shifting toward highly personalized, data-driven therapies, and this partnership secures the nec...